Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [683]

OncoAlert and ecancer weekly round up for July 12- July 18, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 12- July 18, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Cell free DNA BRAF mutant allele fraction and whole exome sequencing in...

Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain

$Cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer ( Dr Elena Elez - Vall d'Hebron University Hospital, Barcelona, Spain )$

OncoAlert and ecancer weekly round up for July 1- July 10, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 1- July 10, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab...

Dr Zev Wainberg - University of California Los Angeles, California, USA

Study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer ( Dr Zev Wainberg - University of California Los Angeles, California, USA )

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris...

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC ( Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, France )

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA...

Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )

Tislelizumab in oesophageal cancer after systemic therapy

Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA

Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

OncoAlert and ecancer ASCO roundup - Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer